Cabozantinib Approved for Renal Cell Carcinoma.
The FDA has approved cabozantinib, a tyrosine kinase inhibitor, for patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy. In a randomized phase III trial, participants who received cabozantinib did better across three efficacy endpoints-progression-free survival, overall survival, and objective response rate-than those given the mTOR inhibitor everolimus.